Investors Getting Picky When It Comes To Buying CRISPR Therapeutics AG (CRSP)

money audit

CRISPR Therapeutics AG (NASDAQ:CRSP) does about 1.34M shares in volume on a normal day but saw 1075492 shares change hands in Friday trading. The company now has a market cap of 4.51B USD. Its current market price is $53.10, marking a decrease of -1.48% compared to the previous close of $53.90. The 52 week high reached by this stock is $91.10 whilst the lowest price level in 52 weeks is $37.55.

CRISPR Therapeutics AG (CRSP) has a 20-day trading average at $58.30 and the current price is -41.71% off the 52-week high compared with 41.41% distance from its 52-week low. The 50-day simple moving average of the closing price is $56.45 and its 200-day simple moving average is $60.58. If we look at the stock’s price movements over the week, volatility stands at 3.46%, which increases to 4.49% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 38.51 to suggest the stock is neutral.

The consensus objective for the share price is $84.52, suggesting that the stock has a potential upside of 37.17% over the period.


TD Cowen downgraded its price target at $30.

CRISPR Therapeutics AG (CRSP) stock is down -4.12% over the week and -8.88% over the past month. Its price is -15.18% year-to-date and -5.60% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of -0.98 above consensus estimates by 1.14. The company’s next earnings report forecasts estimating quarterly EPS at -1.52 and -5.63 for whole year. Expected sales for next quarter are $16.67M, which analysts say will come at $60.71M for the current fiscal year and next year at $333M. In addition, estimates put the company’s current quarterly revenue at an average of $3.54M.

To reach the target analysts have set, the stock logically needs to grow 37.17 percent from here.

The company has a return on investment of -9.43% and return on equity of -11.03%. The beta has a value of 1.69. Price to book ratio is 2.16 and price to sales ratio is 16.60.